Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.
Xingxiang PuChun-Wei XuQian WangWen-Xian WangFang WuXiuyu CaiZhengbo SongJinpu YuWen-Zhao ZhongZhijie WangYong-Chang ZhangJingjing LiuShirong ZhangAnwen LiuWen LiPing ZhanHongbing LiuTang-Feng LvLi-Yun MiaoLingfeng MinGen LinLong HuangJingping YuanZhansheng JiangChuangzhou RaoDongqing LvZongyang YuXiaoyan LiChuanhao TangCheng-Zhi ZhouJunping ZhangHui GuoQian ChuRui MengXuewen LiuJingxun WuJin ZhouZhengfei ZhuWeiwei PanFei PangJintao HuangKai WangFan WuTingting ShenShirui ZouBingwei XuLiping WangYoucai ZhuXinqing LinJing CaiLing XuJisheng LiXiaodong JiaoKainan LiHuijing FengLin WangYingying DuWang YaoXuefei ShiXiaomin NiuDongmei YuanYanwen YaoJing KangJiatao ZhangChao ZhangJianfei FuJianhui HuangYinbin ZhangPingli SunHong WangMingxiang YeDong WangZhaofeng WangYue HaoZhen WangBing WanDonglai LvGang LanShengjie YangLin ShiYina WangBihui LiZhang ZhangZhongwu LiYuan LiZhefeng LiuNong YangHuijuan WangWenbin HuangZhuan HongGuansong WangJiandong WangMeiyu FangYong FangXixu ZhuYi ShenYiping ZhangShenglin MaYong SongYuanzhi LuWenfeng FangZiming LiLin WuPublished in: Thoracic cancer (2023)
The rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cell-surface molecules responsible for transmitting signals that regulate cell growth and differentiation. In non-small cell lung cancer (NSCLC), RET fusion is a rare driver gene alteration associated with a poor prognosis. Fortunately, two selective RET inhibitors (sRETi), namely pralsetinib and selpercatinib, have been approved for treating RET fusion NSCLC due to their remarkable efficacy and safety profiles. These inhibitors have shown the ability to overcome resistance to multikinase inhibitors (MKIs). Furthermore, ongoing clinical trials are investigating several second-generation sRETis that are specifically designed to target solvent front mutations, which pose a challenge for first-generation sRETis. The effective screening of patients is the first crucial step in the clinical application of RET-targeted therapy. Currently, four methods are widely used for detecting gene rearrangements: next-generation sequencing (NGS), reverse transcription-polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC). Each of these methods has its advantages and limitations. To streamline the clinical workflow and improve diagnostic and treatment strategies for RET fusion NSCLC, our expert group has reached a consensus. Our objective is to maximize the clinical benefit for patients and promote standardized approaches to RET fusion screening and therapy.
Keyphrases
- poor prognosis
- end stage renal disease
- copy number
- small cell lung cancer
- clinical trial
- genome wide
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- genome wide identification
- advanced non small cell lung cancer
- cell surface
- patient reported outcomes
- clinical practice
- stem cells
- transcription factor
- bone marrow
- patient reported
- circulating tumor cells
- single molecule
- mesenchymal stem cells
- binding protein
- study protocol
- smoking cessation
- epidermal growth factor receptor
- phase iii